Cargando…
Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study
BACKGROUND: This study was conducted to compare the immunogenicity and safety profile of two quadrivalent influenza vaccines (QIVs) in healthy adults (18–60 years) and elderly (>61 years) participants. METHOD: This phase III study was conducted from March 2018 to April 2018 across 12 sites in Ind...
Autores principales: | Basu, Indraneel, Agarwal, Manish, Shah, Viral, Shukla, Vijay, Naik, Sunil, Supe, Pravin Dinkar, Srivastava, Manoj Kumar, Giriraja, Kanakapura Vrushabaiah, Pinjar, Peersab, Mishra, Pradeep Kumar, Joshi, Shishir, Vijayakumar, Ranjit, van de Witte, Serge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920161/ https://www.ncbi.nlm.nih.gov/pubmed/33957854 http://dx.doi.org/10.1080/21645515.2021.1885278 |
Ejemplares similares
-
Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis
por: Wei, Xia, et al.
Publicado: (2023) -
Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
por: Chen, Jianmin, et al.
Publicado: (2023) -
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in India
por: Kalappanavar, Nijalingappa K., et al.
Publicado: (2022) -
Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023) -
Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
por: Hadigal, Sanjay, et al.
Publicado: (2022)